在患有高级固体瘤的患者中,以模型为基础选择皮下尼沃卢马布剂量
Yue Zhao1, Kinjal Sanghavi1, Amit Roy1
1Bristol Myers Squibb, Princeton, New Jersey, USA.
Clinical pharmacology and therapeutics
|December 20, 2023
概括
皮下用尼沃卢马布 (nivolumab),与氨基酶 (hyaluronidase) 配合或不配合使用,显示出可预测的药理动力学 (PK). 这种皮下配方,每四周服用1200毫克,为癌症治疗提供了静脉注射尼沃卢马布的可行替代方案.
科学领域:
- 药理动力学和药理动力学
- 瘤学 药物开发 药物开发
- 生物制剂的配方 生物制剂的配方
背景情况:
- 静脉注射 (IV) 输入 静脉注射 (IV) 输入 静脉注射 尼沃卢马布的药理动力学 (PK) 已得到充分证实.
- 一种皮下 (s.c.) nivolumab配方,有或没有复合人体氨酶PH20,正在研究中.
- 检查Mate 8KX (NCT03656718) 正在评估这个新的s.c.配方.
研究的目的:
- 使用基于模型的方法来描述s.c.nivolumab的PK.
- 为了预测系统性暴露,无论是IV还是IV. 尼沃卢马布的管理.
- 为指导选择尼沃卢马布s.c.的最佳剂量方案.
主要方法:
- 一个群体PK模型是从现有的静脉注射模型中调整出来的. 通过整合一个S.C.外血管区的模型.
- 估计了s.c.nivolumab的吸收速率常数和生物可用性.
- 从82名接受nivolumab s.c. (720,960或1,200毫克) 的患者获得的血清度-时间数据与静脉注射数据进行了聚合. 数据;使用预测校正视觉预测检查 (pcVPC) 评估模型性能.
主要成果:
- 开发的具有时间变化的清除的两部分模型准确地描述了nivolumab s.c. PK数据,PCVPC证实了这一点.
- 每4周一次1200毫克高血压 (q4w) 的预测暴露量高于批准的3毫克/千克静脉注射. q2w剂量,但低于经过测试的最高安全剂量10 mg/kg. q2w. q2w. q2w. q2w. q2w. q2w. q2w. q2w. q2w. q2w.
- 该模型成功地在s.c.和i.v.两种药物中表征了nivolumab PK. 管理路线. 管理路线.
结论:
- 综合的SC和IV的结合. 人口PK模型提供了尼沃卢马布PK的强有力的特征.
- 基于模型的分析支持对nivolumab s.c.进行了全面的益处风险评估.
- 这些发现为选择1200毫克s.c.q4w进行进一步的III期评估提供了依据.
相关概念视频
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...


